AMRI has entered a multi-year drug substance manufacturing agreement with New River Pharmaceuticals, Inc. Under the agreement, AMRI will manufacture the API in New River’s compound, NRP104, a treatment for attention deficit hyperactivity disorder (ADHD) that is currently under review with the FDA. AMRI participated with New River in the development of the chemical process to manufacture NRP104. Financial terms were not disclosed. “AMRI is delighted to continue its relationship w...